

Susan Dent

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6790128/publications.pdf>

Version: 2024-02-01

72
papers

3,755
citations

218592

26
h-index

138417

58
g-index

75
all docs

75
docs citations

75
times ranked

4810
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2017, 35, 893-911.	0.8	860
2	Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 309-325.	157.7	485
3	Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes. <i>JAMA Oncology</i> , 2016, 2, 751.	3.4	243
4	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. <i>European Heart Journal</i> , 2022, 43, 280-299.	1.0	213
5	Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy. <i>Canadian Journal of Cardiology</i> , 2016, 32, 831-841.	0.8	190
6	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the <scp>Cardio-Oncology Study Group</scp> of the <scp>Heart Failure Association</scp> and the <scp>Cardio-Oncology Council of the European Society of Cardiology</scp>. <i>European Journal of Heart Failure</i> , 2020, 22, 1966-1983.	2.9	184
7	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. <i>Journal of Clinical Oncology</i> , 2021, 39, 1448-1457.	0.8	171
8	Novel Agents and Associated Toxicities of Inhibitors of the PI3K/Akt/mTOR Pathway for the Treatment of Breast Cancer. <i>Current Oncology</i> , 2015, 22, 33-48.	0.9	95
9	Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 295-310.	1.1	83
10	Cardiovascular Manifestations From Therapeutic Radiation. <i>JACC: CardioOncology</i> , 2021, 3, 360-380.	1.7	81
11	HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials. <i>Cancer Treatment Reviews</i> , 2013, 39, 622-631.	3.4	73
12	Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis. <i>European Heart Journal</i> , 2022, 43, 300-312.	1.0	71
13	Population-Based Assessment of Emergency Room Visits and Hospitalizations Among Women Receiving Adjuvant Chemotherapy for Early Breast Cancer. <i>Journal of Oncology Practice</i> , 2015, 11, 126-132.	2.5	56
14	Gemcitabine in the management of metastatic breast cancer: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2008, 108, 319-331.	1.1	51
15	Optimal Systemic Therapy for Early Breast Cancer in Women: A Clinical Practice Guideline. <i>Current Oncology</i> , 2015, 22, 67-81.	0.9	43
16	Cardio-Oncology Education and Training. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2267-2281.	1.2	41
17	Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2022, 145, CIR0000000000001056.	1.6	40
18	Adjuvant Endocrine Therapy for Early Breast Cancer: A Systematic Review of the Evidence for the 2014 Cancer Care Ontario Systemic Therapy Guideline. <i>Current Oncology</i> , 2015, 22, 95-113.	0.9	37

#	ARTICLE	IF	CITATIONS
19	Risk Modelâ€“Guided Antiemetic Prophylaxis vs Physicianâ€™s Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 225.	3.4	37
20	Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy. <i>Journal of Animal Science and Technology</i> , 2016, 3, 79-84.	0.8	37
21	Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-Up. <i>Circulation: Cardiovascular Imaging</i> , 2021, 14, e012459.	1.3	35
22	Systemic Targeted Therapy for her2-Positive Early Female Breast Cancer: A Systematic Review of the Evidence for the 2014 Cancer Care Ontario Systemic Therapy Guideline. <i>Current Oncology</i> , 2015, 22, 114-122.	0.9	32
23	Imaging for distant metastases in women with early-stage breast cancer: a population-based cohort study. <i>Cmaj</i> , 2015, 187, E387-E397.	0.9	29
24	Adjuvant Chemotherapy for Early Female Breast Cancer: A Systematic Review of the Evidence for the 2014 Cancer Care Ontario Systemic Therapy Guideline. <i>Current Oncology</i> , 2015, 22, 82-94.	0.9	29
25	Cardioâ€“oncology care in the era of the coronavirus disease 2019 (COVIDâ€“19) pandemic: An International Cardioâ€“Oncology Society (ICOS) statement. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 480-504.	157.7	29
26	Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis. <i>CJC Open</i> , 2021, 3, 1372-1382.	0.7	28
27	Trastuzumab-Induced Cardiotoxicity: Testing a Clinical Risk Score in a Real-World Cardio-Oncology Population. <i>Current Oncology</i> , 2017, 24, 176-180.	0.9	27
28	Comparison of Framingham risk score and chest-CT identified coronary artery calcification in breast cancer patients to predict cardiovascular events. <i>International Journal of Cardiology</i> , 2019, 289, 138-143.	0.8	25
29	Cardioâ€“Oncology in the Era of the COVIDâ€“19 Pandemic and Beyond. <i>Journal of the American Heart Association</i> , 2020, 9, e017787.	1.6	23
30	Optimizing Cardiovascular Health in Patients With Cancer: A Practical Review of Risk Assessment, Monitoring, and Prevention of Cancer Treatmentâ€“Related Cardiovascular Toxicity. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 501-515.	1.8	23
31	Impact of Stopping Trastuzumab in Early Breast Cancer: A Population-Based Study in Ontario, Canada. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1222-1230.	3.0	23
32	Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 689-699.	1.1	21
33	NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24-hour infusion in advanced malignancies. <i>Investigational New Drugs</i> , 2013, 31, 1522-1529.	1.2	20
34	A Multidisciplinary Perspective on the Subcutaneous Administration of Trastuzumab in HER2-Positive Breast Cancer. <i>Current Oncology</i> , 2019, 26, 70-80.	0.9	20
35	Diastolic dysfunction can precede systolic dysfunction on MUGA in cancer patients receiving trastuzumab-based therapy. <i>Nuclear Medicine Communications</i> , 2019, 40, 22-29.	0.5	20
36	Clinical Experience of Patients Referred to a Multidisciplinary Cardiac Oncology Clinic: An Observational Study. <i>Journal of Oncology</i> , 2015, 2015, 1-5.	0.6	19

#	ARTICLE	IF	CITATIONS
37	Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer. <i>Current Oncology Reports</i> , 2021, 23, 128.	1.8	18
38	Cancer and Cardiovascular Disease: The Complex Labyrinth. <i>Journal of Oncology</i> , 2015, 2015, 1-2.	0.6	17
39	Cardiac Computed Tomography in Cardio-Oncology. <i>JACC: CardioOncology</i> , 2021, 3, 635-649.	1.7	17
40	Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial. <i>BMJ</i> , The, 2021, 375, e066588.	3.0	16
41	The Experience of a Multidisciplinary Clinic in the Management of Early-Stage Breast Cancer Patients Receiving Trastuzumab Therapy: An Observational Study. <i>Cardiology Research and Practice</i> , 2012, 2012, 1-5.	0.5	14
42	An International Survey of Health Care Providers Involved in the Management of Cancer Patients Exposed to Cardiotoxic Therapy. <i>Journal of Oncology</i> , 2015, 2015, 1-4.	0.6	13
43	Strategies to Prevent Cardiovascular Toxicity in Breast Cancer: Is It Ready for Primetime?. <i>Journal of Clinical Medicine</i> , 2020, 9, 896.	1.0	13
44	Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils. <i>Journal of the National Cancer Institute</i> , 2021, 113, 513-522.	3.0	13
45	A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1069-1080.	1.6	12
46	SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA mutant tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS1119-TPS1119.	0.8	12
47	Acute Cardiogenic Shock Induced by Infusional 5-Fluorouracil. <i>Case Reports in Oncological Medicine</i> , 2014, 2014, 1-3.	0.2	9
48	Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression. <i>Oncology Letters</i> , 2014, 7, 866-870.	0.8	8
49	Does integration of Magee equations into routine clinical practice affect whether oncologists order the Oncotype DX test? A prospective randomized trial. <i>Journal of Evaluation in Clinical Practice</i> , 2019, 25, 196-204.	0.9	8
50	The Role and Impact of Social Media in Cardio-oncology During the COVID-19 Pandemic. <i>Current Oncology Reports</i> , 2021, 23, 99.	1.8	8
51	Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 733-741.	1.1	6
52	Relationship between quality of life indicators and cardiac status indicators in chemotherapy patients. <i>Zdravstveno Varstvo</i> , 2021, 60, 199-209.	0.6	6
53	How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients. <i>Current Oncology</i> , 2021, 28, 800-812.	0.9	5
54	A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer. <i>Current Oncology</i> , 2021, 28, 5073-5083.	0.9	5

#	ARTICLE	IF	CITATIONS
55	Factors influencing Oncotype DX use in the management of early breast cancer: A single centre experience. <i>European Journal of Cancer</i> , 2014, 50, 2544-2549.	1.3	4
56	Using the appropriate formula for QT measurement can save lives. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.6	4
57	A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 557-561.	1.1	3
58	Left Ventricular Ejection Fraction Monitoring Adherence Rates. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1094-1097.	2.3	3
59	A phase II study of foretinib in triple-negative, recurrent/metastatic breast cancer: NCIC CTG trial IND.197 (NCT01147484).. <i>Journal of Clinical Oncology</i> , 2012, 30, 1036-1036.	0.8	3
60	Cardiotoxicities of Modern Treatments in Breast Cancer. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 34.	0.4	2
61	Response: Proposing and Meeting the Need for Interdisciplinary Cardio-Oncology Subspecialty Training by Sherry-Ann Brown, MD, PhD and Nicole Sandhu, MD, PhD. <i>Journal of Cardiac Failure</i> , 2016, 22, 936.	0.7	1
62	Impact of an electronic tool in prescribing primary prophylaxis with ciprofloxacin or granulocyte colony-stimulating factor for breast cancer patients receiving TC chemotherapy. <i>Supportive Care in Cancer</i> , 2016, 24, 3185-9.	1.0	1
63	A randomized, double-blind trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronate in patients with high-risk bone metastases from breast cancer (The Odyssey) Tj ETQq1 1 @784314 µgBT /Ov		
64	Adjuvant trastuzumab (T) in early stage breast cancer (EBC): Is cardiac dysfunction (CD) clinically significant?. <i>Journal of Clinical Oncology</i> , 2007, 25, 11072-11072.	0.8	1
65	Toxicities and adherence rates of hormone treatment in male breast cancer patients treated at a tertiary care center. <i>Journal of Clinical Oncology</i> , 2009, 27, e11613-e11613.	0.8	1
66	Duration of Trastuzumab. In matters of the heart, one size may not fit all?. <i>European Journal of Cancer</i> , 2015, 51, 1657-1659.	1.3	0
67	Progress in Breast Cancer—Can We Do Better?. <i>Current Oncology</i> , 2018, 25, 7-8.	0.9	0
68	Adverse thrombo-embolic events with newer tyrosine kinase inhibitors: a call to action for better risk stratification and monitoring. <i>European Journal of Preventive Cardiology</i> , 2021, , .	0.8	0
69	Trends in systemic management (SM) for the treatment of locally advanced breast cancer: Data from a regional cancer centre. <i>Journal of Clinical Oncology</i> , 2006, 24, 10728-10728.	0.8	0
70	Validation of heart failure prediction tool in cardio-oncology breast cancer population.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17693-e17693.	0.8	0
71	Does Diastolic Dysfunction Precede Systolic Dysfunction Following Contemporary Breast Cancer Therapy?. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 1454-1455.	2.3	0
72	Ontario Cancer Research Ethics Board (OCREB): A central research ethics board initiative. <i>Journal of Clinical Oncology</i> , 2004, 22, 6094-6094.	0.8	0